Region Skane Hassleholm Hospital
- Address
- lock Available on a paid plan
Acute Ischemic Stroke
The Hip and Knee unit at Region Skane Hassleholm Hospital is conducting research focused on Acute Ischemic Stroke and high‑risk transient ischemic attacks, integrating diagnostic imaging and therapeutic techniques to improve patient outcomes.
- Assessing a novel oral anticoagulant for reducing recurrent stroke events
- Exploring early initiation of targeted therapy within hours of symptom onset
- Measuring functional recovery three months after treatment
These studies aim to provide safer, more effective options for preventing further cerebrovascular events and enhancing recovery after stroke.
Prosthetic Joint Infection
In the area of Musculoskeletal Diseases, investigators are evaluating strategies to lower infection risk following hip replacement surgeries.
- Testing antibiotic‑impregnated bone grafts as a protective measure
- Comparing infection rates two years post‑arthroplasty
- Analyzing long‑term implant stability and patient safety
The goal is to reduce prosthetic joint infections, thereby improving the durability of hip arthroplasties and patient quality of life.
Outpatient Total Knee and Hip Arthroplasty
Research within the Operative Procedures field examines anesthesia choices for same‑day discharge after primary total knee and hip replacements.
- Comparing general anaesthesia with spinal anaesthesia on discharge success
- Tracking readmission rates within 48 hours of surgery
- Evaluating patient comfort and postoperative mobility
Findings will guide best practices for outpatient joint surgery, aiming to increase same‑day discharge rates while maintaining safety.
Cardiovascular Disease Prevention
The site’s investigations also address Cardiovascular Diseases, focusing on novel anticoagulant therapy to prevent further ischemic events after an initial stroke.
- Determining efficacy of a new oral anticoagulant in reducing stroke recurrence
- Monitoring safety profile and bleeding risk
- Assessing overall cardiovascular outcomes over a multi‑year period
This work seeks to expand treatment options for patients at high risk of subsequent cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Karolinska Institutet1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Skane Hassleholm Hospital
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.